Last checked at 3 Oct 2012 07:00
Oxford BioMedica plc Board Change
-- Appointment of New Non-Executive Director --
Oxford, UK - 3 October 2012: Oxford BioMedica ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces the appointment of Martin Diggle as a non-Executive Director of the Company, effective as of 4 October 2012.
Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Oxford BioMedica's largest shareholder. An investment professional with over 29 years' experience in investment banking and fund management, Martin has extensive, first-hand knowledge of the global financial markets. Martin is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade. Martin holds a master's degree in Philosophy, Politics and Economics from University of Oxford.
Nick Rodgers, Chairman of Oxford BioMedica, said: "Martin has been a long-term supporter of Oxford BioMedica and I am delighted to welcome him to the Board. With a wealth of financial investment experience and a strong international reputation, Martin's contribution will be invaluable as we continue to attract further investment into the Company and implement our growth strategy."
There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.
-Ends-
For further information, please contact: | |
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications | Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications |
Tel: +44 (0)20 7920 2333
|
Notes to editors
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.